Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$10.98 USD

10.98
14,009,585

-0.04 (-0.36%)

Updated May 17, 2024 04:00 PM ET

After-Market: $10.97 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?

AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.

Viatris (VTRS) Dips More Than Broader Markets: What You Should Know

Viatris (VTRS) closed the most recent trading day at $15.03, moving -0.92% from the previous trading session.

Why Viatris (VTRS) Could Beat Earnings Estimates Again

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

Viatris (VTRS) closed the most recent trading day at $15.22, moving -0.26% from the previous trading session.

Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease

Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.

Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know

Viatris (VTRS) closed at $15.30 in the latest trading session, marking a +1.53% move from the prior day.

Viatris (VTRS) Stock Moves -0.21%: What You Should Know

Viatris (VTRS) closed the most recent trading day at $14.59, moving -0.21% from the previous trading session.

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Viatris (VTRS) closed at $14.36, marking a -1.17% move from the previous day.

Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Viatris (VTRS) closed at $15.22, marking a +1.33% move from the previous day.

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

Viatris (VTRS) closed the most recent trading day at $15.17, moving -0.98% from the previous trading session.

Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year

Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.

Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View

Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.

Viatris (VTRS) Q3 Earnings and Revenues Surpass Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 15.12% and 3.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More

Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.

Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track

Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.

Viatris (VTRS) Gains But Lags Market: What You Should Know

In the latest trading session, Viatris (VTRS) closed at $13.83, marking a +0.07% move from the previous day.

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.

Earnings Preview: Viatris (VTRS) Q3 Earnings Expected to Decline

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 33% Upside in Viatris (VTRS): Can the Stock Really Move This High?

The mean of analysts' price targets for Viatris (VTRS) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.

Why Is Viatris (VTRS) Down 3% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug

J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.

Theravance (TBPH) Suffers 2nd Study Failure in Two Months

Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.